Drug intelligence / Profile preview

IGT-303

Development stage: Phase 2
Lead developer: Ingenia Therapeutics

Overview

IGT-303 is a novel biological therapeutic under development by Ingenia Therapeutics. It acts as an agonist of the TIE-2 receptor, a key regulator of vascular stability and angiogenesis. The drug is classified as a new molecular entity and is currently in preclinical development for an undisclosed indication. The specific disease area has not been publicly disclosed, but the mechanism suggests potential relevance to conditions involving vascular dysfunction or inflammation[1][2].

Other names: IGT 303IGT303IGT-303

Targets

TEK (Tie2)

Beyond the preview

Go deeper on IGT-303.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IGT-303.